Romidepsin is effective and well-tolerated in patients ≥60 years old with relapsed or refractory peripheral T-cell lymphoma (PTCL): analysis from phase 2 trials.
D000368:Aged; D000903:Antibiotics, Antineoplastic / Q000627:therapeutic use*; D047630:Depsipeptides / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D016411:Lymphoma, T-Cell, Peripheral / Q000188:drug therapy*; D008875:Middle Aged; D012008:Recurrence
D000903:Antibiotics, Antineoplastic; D047630:Depsipeptides; C087123:romidepsin